# Real, and Below the Threshold

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/real-and-below-the-threshold

> Semaglutide improves patient-reported physical functioning by 1.71 points, with an interval excluding zero. The threshold at which a patient notices a change is 3.7 points. Both are true at once.

## Key points

- Physical functioning +1.71 points (CI 1.07–2.35) against a 3.7-point threshold for noticing.
- The change is statistically real and below the clinical threshold at the same time.
- Two earlier studies we covered reached the same place, and this review makes the third.
- The exception is disease-specific. Heart failure trials cleared their threshold.
- Every trial comes from the manufacturer's own development program. There is no independent evidence.

Semaglutide improves patient-reported physical functioning. The improvement is **1.71 points**, with a confidence interval from 1.07 to 2.35 that comfortably excludes zero, so it is real. The threshold at which a patient would *notice* a change is 3.7 points.[1] Both are true at once, and the gap between them is the difference between statistical and clinical significance.

## Two different bars

Statistical significance asks whether an effect is distinguishable from chance. Clinical significance asks whether it is large enough to matter to the person experiencing it. They are separate questions with separate answers, and a result can clear one bar and fail the other.

Here, the *meaningful within-patient change* threshold is a number researchers establish in advance, by asking patients how much a score has to shift before they perceive a difference. For this instrument it is 3.7 points. The drug delivers 1.71.

> Physical functioning improved by 1.71 points, less than half the 3.7 points at which patients notice a change.

The same pattern held on a second, weight-specific instrument across two trials and 2,768 participants: larger effects in people without type 2 diabetes, smaller in people with it, and **both below the published thresholds**.

## The picture this completes

Two earlier studies we have covered arrived at the same place by different routes, and this review makes the third. A fourth, in heart failure, found the opposite.

*What the evidence says about quality of life on these drugs.*

| Source | Finding |
| --- | --- |
| [Network meta-analysis of 262 trials](https://glpwatchdog.org/research/what-262-trials-say-together) | No drug improved quality of life beyond the threshold, across 43 trials and 45,663 participants |
| [The head-to-head trial](https://glpwatchdog.org/research/the-mental-health-score-that-did-not-move) | The mental component improved in **neither** arm over 72 weeks |
| This review | Physical functioning improved **statistically**, and below the threshold patients notice |
| [The two heart failure trials](https://glpwatchdog.org/research/the-one-place-people-felt-better) | **Cleared the threshold** — +7.8 and +6.9 points against a bar of about 5 |

> **The last row is what resolves the other three.** The heart failure trials used a questionnaire built from the symptoms of one disease, in people who have that disease and whose drug treats it. The others used general health surveys, which average across everything in a life. A specific instrument in the right disease finds what a general one dilutes to nothing.

So the supportable claim is narrow and consistent: **there is no good evidence these drugs make people feel better in general**, and there is good evidence they relieve the symptoms of specific conditions they treat.

## Who ran every one of these trials

> **The authors state it directly: the available randomized evidence comes from the semaglutide development program.** Every trial in this analysis belongs to the manufacturer. There is no independent randomized evidence at all, conflicting or otherwise, on what these drugs do to quality of life.

That matters less than it might, because the finding is a modest one. A sponsor’s own trials reporting an improvement smaller than patients would notice is not the direction bias usually runs. If anything, it makes the result more credible than a larger one from the same source would be.

Heterogeneity was moderate at 52.8%, which is unremarkable for a pooled analysis but worth keeping in mind alongside the narrow confidence interval.

## What to do with it

- **Physical improvement may be larger if you lose more weight**, but this review did not test that link, and its average gain was below what patients notice.
- **Do not plan on feeling better in general.** If that is the main reason for starting, this is the evidence to weigh, and it is not encouraging.
- **The exception is real and specific.** In obesity-related heart failure, these drugs relieve the symptoms of that condition by an amount patients notice.
- **“Statistically significant” is not a synonym for “you will feel it.”** When a paper reports an improvement, look for whether it names a threshold and whether the effect cleared it.

The authors’ own conclusion is that the gains are modest and should be communicated cautiously. That is an unusually plain thing for a paper to say about a positive finding, and it is the right instruction.

## Frequently asked questions

### Does semaglutide improve quality of life?

It improves patient-reported physical functioning by 1.71 points, with a confidence interval excluding zero, so the effect is real. The threshold at which patients perceive a change on that instrument is 3.7 points, so it falls below what someone would notice.

### How can something be statistically significant and not matter?

Statistical significance asks whether an effect is distinguishable from chance. Clinical significance asks whether it is big enough for the person to feel. A large, well-conducted analysis can establish a small effect very precisely, and this is that case.

### Is that true for everyone?

Effects were larger in people without type 2 diabetes and smaller in those with it, and both remained below the published thresholds on a second weight-specific instrument.

### Do these drugs ever produce a noticeable improvement?

Yes, in a specific case. In obesity-related heart failure, trials using a questionnaire built from that condition's symptoms found improvements of 7.8 and 6.9 points against a threshold of about 5. That is a disease-specific instrument in a disease the drug treats.

### Who conducted these trials?

All of them come from the semaglutide development program, as the authors state. There is no independent randomized evidence on quality of life with these drugs. That matters less than usual here, since a sponsor reporting an effect smaller than patients would notice is not the direction bias normally runs.

## References

1. Eisa N, Khoury M. The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. 2026. PMID: 42297754. https://pubmed.ncbi.nlm.nih.gov/42297754/

---

Cite as: GLP Watchdog, Nora Bissett, "Real, and Below the Threshold", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/real-and-below-the-threshold

Canonical HTML page: https://glpwatchdog.org/research/real-and-below-the-threshold

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
